Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer : the Epidemiology of Endometrial Cancer Consortium

Show full item record



Permalink

http://hdl.handle.net/10138/312608

Citation

Webb , P M , Na , R , Weiderpass , E , Adami , H O , Anderson , K E , Bertrand , K A , Botteri , E , Brasky , T M , Brinton , L A , Chen , C , Doherty , J A , Lu , L , McCann , S E , Moysich , K B , Olson , S , Petruzella , S , Palmer , J R , Prizment , A E , Schairer , C , Setiawan , V W , Spurdle , A B , Trabert , B , Wentzensen , N , Wilkens , L , Yang , H P , Yu , H , Risch , H A & Jordan , S J 2019 , ' Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer : the Epidemiology of Endometrial Cancer Consortium ' , Annals of Oncology , vol. 30 , no. 2 , pp. 310-316 . https://doi.org/10.1093/annonc/mdy541

Title: Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer : the Epidemiology of Endometrial Cancer Consortium
Author: Webb, P. M.; Na, R.; Weiderpass, E.; Adami, H. O.; Anderson, K. E.; Bertrand, K. A.; Botteri, E.; Brasky, T. M.; Brinton, L. A.; Chen, C.; Doherty, J. A.; Lu, L.; McCann, S. E.; Moysich, K. B.; Olson, S.; Petruzella, S.; Palmer, J. R.; Prizment, A. E.; Schairer, C.; Setiawan, V. W.; Spurdle, A. B.; Trabert, B.; Wentzensen, N.; Wilkens, L.; Yang, H. P.; Yu, H.; Risch, H. A.; Jordan, S. J.
Contributor: University of Helsinki, Department of Medical and Clinical Genetics
Date: 2019-02
Language: eng
Number of pages: 7
Belongs to series: Annals of Oncology
ISSN: 0923-7534
URI: http://hdl.handle.net/10138/312608
Abstract: Background: Regular use of aspirin has been associated with a reduced risk of cancer at several sites but the data for endometrial cancer are conflicting. Evidence regarding use of other analgesics is limited. Patients and methods: We pooled individual-level data from seven cohort and five case-control studies participating in the Epidemiology of Endometrial Cancer Consortium including 7120 women with endometrial cancer and 16 069 controls. For overall analyses, study-specific odds ratios (ORs) and 95% confidence intervals (CI) were estimated using logistic regression and combined using random-effects meta-analysis; for stratified analyses, we used mixed-effects logistic regression with study as a random effect. Results: At least weekly use of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an approximately 15% reduced risk of endometrial cancer among both overweight and obese women (OR 1/4 0.86 [95% CI 0.760.98] and 0.86 [95% CI 0.76-0.97], respectively, for aspirin; 0.87 [95% CI 0.76-1.00] and 0.84 [0.74-0.96], respectively, for nonaspirin NSAIDs). There was no association among women of normal weight (body mass index<25 kg/ m2, Pheterogeneity 0.04 for aspirin, Pheterogeneity 1/4 0.003 for NSAIDs). Among overweight and obese women, the inverse association with aspirin was stronger for use 2-6 times/ week (OR 1/4 0.81, 95% CI 0.68-0.96) than for daily use (0.91, 0.80-1.03), possibly because a high proportion of daily users use low-dose formulations. There was no clear association with use of acetaminophen. Conclusion: Our pooled analysis provides further evidence that use of standard-dose aspirin or other NSAIDs may reduce risk of endometrial cancer among overweight and obese women.
Subject: endometrial cancer
aspirin
nonsteroidal anti-inflammatory drugs
acetaminophen
HEREDITARY COLORECTAL-CANCER
LONG-TERM USE
INFLAMMATION
PARACETAMOL
EXPRESSION
VITAMINS
CARRIERS
OVARIAN
NSAID
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
mdy541.pdf 246.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record